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R E S E A R C H  L E T T E R
Gene signatures from scRNA-seq accurately quantify mast cells 
in biopsies in asthma
To the Editor:
Respiratory disease, characterized by changes in the cells of the 
lung, can affect molecular phenotype of cells and the intercellular 
interactions, resulting in a disbalance in the relative proportions of 
individual cell types. Understanding these changes is essential to un-
derstand the pathophysiology of lung disease. Conventional “bulk” 
RNA sequencing (RNA-seq), analysing the entire transcriptome of 
the tissue sample, provides information about average expression 
levels of each gene in the mixed cell population, whereas it does not 
consider the cellular heterogeneity in samples composed of more 
than one cell type.1 Single-cell RNA-seq (scRNA-seq) assesses the 
transcriptome of a complex biological sample with single-cell reso-
lution, allowing identification of the relative frequency of discrete 
cell types and analysis of their transcriptomes.1 Nevertheless, ana-
lysing the transcriptomic signature in large numbers of patients by 
scRNA-Seq is currently limited by its high costs. Mast cells are key 
regulatory cells driving the inflammatory process in asthma.2 Since 
they can be quantified by immunohistochemical staining for valida-
tion purposes, we used mast cells as an example of a rare cell popu-
lation to assess the validity of our deconvolution approach. Recently, 
a number of bulk RNA-seq deconvolution methods have become 
available,3 for instance of two deconvolution methods, namely sup-
port vector regression (SVR),4 the machine-learning method imple-
mented in CIBERSORT and non-negative least square (NNLS),5 using 
a matrix of cell type selective genes identified with AutoGeneSc.6 
Both approaches are designed to estimate relative proportion of the 
main, common cell types present in the sample. When we used these 
methods to estimate the number of mast cells, we found a poor cor-
relation with the number of mast cells stained by immunohistochem-
istry in the biopsies, suggesting the CIBERSORT and NNLS are less 
reliable in the case of rare cell types. We explored the possibility to 
use scRNA-Seq data from small numbers of subjects to specifically 
interrogate the relative cell type frequency of a rare cell population in 
a bulk RNA-Seq data set obtained from a large asthma cohort.
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TA B L E  1   Patient characteristics




PC20AMP (mg/mL) median [min, max] 59.9 [0.002, 640.0] 45.4 [0.02, 640.0]
FEV1 (%pred) mean [SD] 84.6 [18.12] 83.2 [12.43]
ICS dose (µg/d) median[min, max] 800 [28, 2000] NA
Beta-agonist use (n(%)) 40 (91%) 13 (52%)
Sex (m/f) 19/25 14/11
Age (y) mean [SD] 47.7 [12.45] 45.4 [12.50]
FEV1/FVC (%) mean [SD] 70.2 [10.31] 70.2 [8.24]
Reversibility FEV1 (%) mean [SD] 9.2 [6.58] 9.6 [6.14]
Atopy (phadiatop) (n(%)) 10 (76) 5 (78)
Current smoking status (Yes, No) 6/38 9/16
Blood eosinophils (*10^9/L) median [min, max] 0.18 [0.04, 0.78] 0.25 [0, 0.9]
Note: Asthma patients included in the study were defined by same criteria as described.13
Abbreviations: FEV1, forced expiratory volume at timed intervals of 1.0; FVC, forced vital capacity.
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We analysed the scRNA-Seq data7 of bronchial biopsies from 6 
asthma patients and 6 matched healthy controls. scRNA-Seq data 
can be accessed at European Genome-phenome Archive (EGA) (ac-
cession number: EGAS00001002649). Unsupervised clustering of 
the 27 213 cells obtained from the 12 subjects identified 11 clusters, 
including those containing epithelial cells (92.19%), endothelial cells 
(2.14%), fibroblasts (0.59%), smooth muscle cells (0.22%) and the 
cluster comprising multiple lymphocyte subsets (4.86%). Mast cells 
were the smallest cluster (0.20%). The healthy subjects contained 
few or no mast cells (0.026% of all cells) in their biopsies, while the 
abundance of mast cells was clearly increased in the asthma patients 
(0.176%).7 In the cluster of mast cells, the relative expression levels 
of TPSB2, TPSAB1, PTGS2 and HPGDS were significantly higher (Top 
50 highly expressed genes) than their mean expressions in any other 
clusters.7
To identify a gene signature that was specific and selective for 
mast cells in a mixed tissue sample, we selected only those genes 
that met the following criteria in the scRNA-Seq data: (a) >70% 
of all reads of the gene measured in the total scRNA-Seq data set 
mapped to the mast cell cluster; (b) the minimum cumulative num-
ber of reads expressed by all cells in the mast cell cluster >100; 
and (c) the minimum number of reads expressed by each cell in the 
mast cell cluster that expresses the gene ≥2, but dropouts (non-ex-
pressing cells) are allowed. Because mast cells were nearly absent 
in healthy subjects, we only used the scRNA-Seq data from the 6 
asthma patients to generate the mast cell-specific gene list. The 
criteria resulted in 11 mast cell-specific genes: TPSB2, TPSAB1, 
TPSD1, TESPA1, RGS13, SLC18A2, CPA3, MS4A2, HPGDS, ADCYAP1 
and HDC, with, respectively, 84.8%, 83.5%, 79.3%, 78.7%, 78.2%, 
74.6%, 74.5%, 73.4%, 72.7%, 71.3% and 70.8% of reads mapping 
F I G U R E  1   Relationship between mast cell gene signature and measurements of their cell counts in biopsy samples. A, The mast 
cell signature is positively correlated with the tryptase-containing mast cells (AA1+) in biopsy samples from 69 asthma patients. B, The 
composite score of the mast cell gene signature is significantly decreased in asthma patients receiving ICS than in patients without ICS. C, 
The numbers of mast cells (AA1+) are reduced in asthma patients with ICS treatment compared to patients without ICS
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to the mast cell cluster. TPSB2, TPSAB1, TPSD1 and CPA3 encode 
the well-known mast cell proteases.8,9 MS4A2, HPGDS and HDC 
were also reported as genes encoding well-defined mast cell mark-
ers.10 Microarray-based genome-wide expression patterns of air-
way epithelial brushings showed that TPSB2, TPSAB1 and CPA3 
(ranked 4-6) were among the most differentially expressed genes 
associated with asthma.2 Human mast cells produce three soluble 
forms of tryptases: α (TPSAB1)-, β (TPSB2)- and δ-tryptase (TPSD1).8 
Particularly, anti-TPSAB1 antibody serves as a marker (AA1+) for 
indicating the presence and activity of mast cells.11 There are two 
mast cell phenotypes, one expressing high levels of tryptase but 
little or no chymase and one expressing tryptase, chymase and 
CPA3.11,12 Although the expression of CMA1 (chymase-coding gene) 
was not detected in our scRNA-Seq data, TPSB2, TPSAB1, TPSD1 
and CPA3 were all identified as the mast cell-specific genes, sug-
gesting the genes selected by our approach likely represent both 
mast cell subtypes.
To test whether the mast cell gene signature could quantify their 
abundance in bulk RNA-Seq data, we used a data set of bronchial 
biopsies from 69 asthma patients either on (n = 44) or off (n = 25) 
inhaled corticosteroid (ICS) treatment13 (Table 1). Sample collection, 
RNA extraction, library preparation, sequencing and data analysis 
were processed as described.14 Bulk RNA-seq data have been de-
posited at the EGA (accession number: EGAS00001003735). Since 
we intended to study the genome-wide expression of rare cells from 
a population of cells, we did not exclude lowly expressed genes. In 
total, 55 269 unique Ensembl gene IDs (mapping to 1597 unique 
human genes) were available for analyses.
We calculated the sum of the log2-transformed fragments 
per kilobase of transcript per million fragments mapped (FPKM) 
values of the 11 genes for each patient and used the composite 
value as the mast cell gene score. Then, we correlated the mast 
cell gene score to mast cell numbers determined by immunohis-
tochemical staining of TPSAB1 (AA1) in matched biopsies. In 
the 69 asthma patients, the mast cell-specific 11-gene signature 
was significantly correlated with mast cell numbers in biopsies 
(Pearson, r = 0.42, P < .001, FDR = 0.0084) (Figure 1A), although 
more stringent selection of mast cell-specific genes (>75% and 
>80% of reads mapped to the mast cell cluster, resulting in 5-gene 
and 2-gene signatures, respectively) worked equally well. In the 
44 asthma patients taking ICS, the average mast cell gene scores 
were significantly lower (median = 4.45 ± 1.13) than those found 
in the 25 asthma patients without ICS usage (median = 5.12 ± 0.78 
and P = .013, Mann-Whitney test) (Figure 1B). Interestingly, the 
AA1 staining revealed only a trend towards decreased numbers 
of mast cells in the biopsies of ICS-treated asthma patients (me-
dian = 6.11 ± 5.15) compared to the patients without taking ICS 
(median = 10.83 ± 7.85, P = .087, Mann-Whitney test) (Figure 1C). 
These were consistent with the findings that ICS treatment re-
duced the number and activity of mast cells within the airway epi-
thelium and smooth muscle.15
Overall, our approach, calculating a composite score for mast 
cell-specific genes, captures the transcript abundance of the mast 
cells and thus (a) can accurately quantify mast cell gene expression 
in bulk RNA-seq and (b) may reflect both the number and activity of 
mast cells in the airway epithelium, complementing the IHC-based 
mast cell counts with information about behaviour of cells in biopsy 
sections.
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